From August 18th 2026, GtoPdb will require users to register to use the website. Please see our blog post for more information.

CFT1946   Click here for help

GtoPdb Ligand ID: 12623

Synonyms: CFT-1946
Compound class: Synthetic organic
Comment: CFT1946 is an orally bioavailable, mutant-seelctive BRAFV600X PROTAC type degrader, that was developed for anti-tumour potential. It uses a cereblon (CRBN)-binding moiety to engage the E3 ubiquitin ligase system. The chemical structure was disclosed during the 'First Disclosures of New Drug Candidates' session at the April 2023 (Orlando) meeting of the AACR.

CFT1946 is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 20
Hydrogen bond donors 3
Rotatable bonds 12
Topological polar surface area 241.5
Molecular weight 958
XLogP 0.77
No. Lipinski's rules broken 3

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES CCN(C)S(=O)(=O)NC1=CC=C(C(=C1C#N)OC2=CC3=C(C=C2)N=CN([C@@H]4CC5(CCN(CC5)C(=O)CC6(CCN(CC6)C7=CC8=C(C=C7F)C(=NN8C)N9CCC(=O)NC9=O)O)OC4)C3=O)F
Isomeric SMILES CCN(C)S(=O)(=O)NC1=CC=C(F)C(OC2=CC3=C(C=C2)N=CN([C@H]4COC5(C4)CCN(CC5)C(=O)CC6(O)CCN(CC6)C7=CC8=C(C=C7F)C(=NN8C)N9CCC(=O)NC9=O)C3=O)=C1C#N
InChI InChI=1S/C45H49F2N11O9S/c1-4-53(2)68(64,65)52-35-8-6-32(46)40(31(35)24-48)67-28-5-7-34-29(19-28)42(61)58(26-49-34)27-22-45(66-25-27)12-17-56(18-13-45)39(60)23-44(63)10-15-55(16-11-44)37-21-36-30(20-33(37)47)41(51-54(36)3)57-14-9-38(59)50-43(57)62/h5-8,19-21,26-27,52,63H,4,9-18,22-23,25H2,1-3H3,(H,50,59,62)/t27-/m1/s1
InChI Key OCDRMYDQTIPVOI-HHHXNRCGSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
CFT1946 has been progressed to clinical evaluation, in a trial that was initiated in December 2022. NCT05668585 is recruiting patients with advanced, solid tumours that harbour BRAFV600 mutations.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05668585 A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and in Combination With Trametinib in Subjects With BRAF V600 Mutant Solid Tumors Phase 1/Phase 2 Interventional C4 Therapeutics, Inc.